The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksHigh Impact•16 April 2026•

1 min read

PDS Biotech Reports Positive Phase 2 Data for Colorectal Cancer Treatment

Key Facts

1PDS Biotech announced a 78% Objective Response Rate (ORR) for PDS01ADC in Phase 2 trials.

2The 2-year survival rate exceeded 80% compared to approximately 35% in parallel trials without the drug.

PDS Biotechnology has announced promising interim Phase 2 clinical trial data for its PDS01ADC treatment targeting metastatic colorectal cancer. The data, released in collaboration with the National Cancer Institute (NCI), revealed a significant 78% Objective Response Rate (ORR), substantially outperforming current benchmarks. Furthermore, the study highlighted a 2-year survival rate exceeding 80%, compared to approximately 35% in parallel trials without the drug. These robust clinical results suggest high potential for future regulatory approvals and strengthen the company's competitive position in the oncology sector. Investors are viewing these developments as a major catalyst for PDSB stock amid improving prospects for immunotherapy. This update marks a critical milestone in providing more effective treatment options for patients with advanced stages of the disease.